Show simple item record

dc.contributor.authorMartínez Alonso, Montserrat
dc.contributor.authorAriza Carrió, Gemma
dc.contributor.authorDusso Rosso, Adriana
dc.contributor.authorNabal Vicuña, Maria
dc.date.accessioned2015-11-17T10:39:56Z
dc.date.available2015-11-17T10:39:56Z
dc.date.issued2015
dc.identifier.issn2044-6055
dc.identifier.urihttp://hdl.handle.net/10459.1/48971
dc.description.abstractIntroduction: Vitamin D is related to resistance to chronic diseases, physiological parameters and functional measures. All of these relationships underscore the potential benefits of cholecalciferol or D3 (nutritional vitamin D) in cancer. This is the first study designed to obtain conclusive evidence on the effect of cholecalciferol in advanced patients with cancer. The main goal is to assess its effects on the patient’s perceived quality of life. Cholecalciferol’s impact on fatigue and physical performance, as well as its cost utility, will also be assessed. Methods and analysis: A randomised triple-blind phase II/III placebo-controlled multicentre trial has been designed. Patients satisfying the inclusion and exclusion criteria will be randomly assigned to receive cholecalciferol or placebo. Eligible patients will be adults with a locally advanced or metastatic or inoperable solid cancer in palliative care, who have given signed informed consent and have matched inclusion and exclusion criteria. The randomisation will be based on a computer-generated procedure and centralised by the pharmacy service of the coordinating centre. The assigned treatment will be administered by the hospital’s pharmacy to conceal group allocation for patients and healthcare providers. Cholecalciferol (4000 IU/day) or placebo, starting at day 15 and continuing up to day 42, will be added to palliative care treatment. Outpatient visits will be scheduled every 14 days. Ethics and dissemination: Ethical approval was received from the Medical Ethical Commitee of the HUAV (CEIC-1169). Participants and their families will receive the research findings which will also be disseminated on local and national media, presented at national and international meetings of the specialty, and published in peer-reviewed scientific journals. Trial registration number: EudraCT: 2013-003478-29ca_ES
dc.language.isoengca_ES
dc.publisherBMJ Publishing Groupca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1136/bmjopen-2014-006128ca_ES
dc.relation.ispartofBMJ Open, 2015, vol. 4, núm 12, p. 1-7ca_ES
dc.rightscc-by-nc (c) Martínez Alonso, Montserrat et al., 2015ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.titleThe effect on quality of life of vitamin d administration for advanced cancer treatment (vidafact study): Protocol of a randomised controlled trialca_ES
dc.typearticleca_ES
dc.identifier.idgrec022422
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1136/bmjopen-2014-006128


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by-nc (c) Martínez Alonso, Montserrat et al., 2015
Except where otherwise noted, this item's license is described as cc-by-nc (c) Martínez Alonso, Montserrat et al., 2015